bt-protect

Bio-Therapeutic is proud to announce the development and introduction of its new
bt-protect skincare safety suite. Developed in response to the new standards for industry professionals as they return to work, this dynamic, ergonomic, and thoughtful skincare safety suite addresses new sanitation and cleanliness standards for close contact workers.
Created for skincare, hair, nail, and other high touch fields, bt-protect equipment is designed to provide a layer of reassurance for clients and service providers alike. The suite currently consists of three attentively designed tools that provide the ultimate in modern technology protection.

bt-degree IR

The bt-degree IR touchless infrared thermometer adds a layer of crucial safety to the healthy function of your practice intake process. Capable of both Fahrenheit and Celsius measurements, the bt-degree IR takes forehead temperature in approximately 1 second and eliminates contact with effectiveness from up to 2 inches away. The blue aiming light, large display, color coded LCD screen and audible alerts make the bt-degree IR easy to use and understand. The 9 reading memory and 1 button measurement makes it simple to use. The bt-degree IR is protected by a silicone carrying case and silicone sleeve, both infused with Silver Ion. The bt degree IR is also a Class 2 FDA and CE medical device classified for over the counter use.





The bt-smartmask
This reusable, three layer fabric is silver ion infused in its central core to provide multi layer protection yet breathability for all day wear. This unique mask is an environmentally conscious option for the professional over frequently replaced disposable paper masks. The revolutionary facial contour molded design and athletic style weave is supremely protective yet comfortable for the wearer while also being fully adjustable.

bt-shield
An essential part of your post Covid-19 skincare safety suite, the bt-shield is a lightweight, reusable, sanitizable, protective face guard. Featuring Bio-Therapeutic’s unique silicone touch points infused with silver ion properties where the shield encounters the skin. The bt-shield is made of superior quality anti-fog, anti-scratch clear PET plastic that is additionally distortion free. These unique benefits provide viewing clarity yet supreme safety reassurance for the professional. Prescription glass wearers have also been carefully considered; the strategically extended nose bridge touch points allow for glasses to be worn comfortable together with the
bt-shield.
“Created for skincare, hair, nail, and other high touch fields, bt-protect equipment integrates the latest antimicrobial and any bacterial properties of silver ion, designed to provide a layer of reassurance” – David Suzuki, President Bio-Therapeutic



2069385800  www.bio-therapeutic.com

Read more...

Technology to the Rescue: Keeping Up with Cosmetics

Virtual consultations in plastic surgery or medical spa practice are more important than ever before. It is a great tool for out-of-town patients to receive a preliminary evaluation and prepare for their treatment prior to coming into the office.

Virtual consultations prior to COVID-19 may not have been the priority for some spas, but now they are becoming an important aspect of a spa business. With the stay-at-home order, virtual consultation rate have increased significantly.

Although virtual consultations are not a substitute to in-person exams, it is a great time to take advantage of this option. A virtual consultation will initiate a relationship that can be easily expanded as services can resume. This will serve to be extremely valuable when skin care professionals and clients do finally meet; the relationship will have already been established and the goal will be clear.

 

VIRTUAL CONSULTATIONS

The process is simple: it starts with the client submitting all necessary forms, as well as images capturing all views of the area they would like to treat. Once the chart is created, have the team coordinate a Skype, Zoom, or regular phone call with the client, revising all preliminary details. Once all questions are answered, the client start their surgical planning process. Almost all procedures can, to a certain degree, be conducted virtually.

The goal of the virtual consultation is to initiate a relationship and dive into the preliminary idea of the client’s goals and desires. While a virtual consultation does not replace a physical exam, the professional can still complete a high percentage of the prep evaluation and formulate a preliminary plan.

Once the virtual session is over, the client has a very good idea if their desire is achievable – to a certain limited degree. Send additional materials electronically and have clients review before-and-after pictures on the spa’s website or portal, read the materials pertinent to their case, and conclude with a reasonable idea of what can be accomplished.

Overall, be sure to make the client feel comfortable by explaining the procedure, techniques, or treatment. Holding a virtual consultation with a client can be easy when these steps are utilized.

 

 

Dr. Thomas Trevisani, often referred to as Dr. Tom, is a Board Certified Plastic Surgeon who specializes in Rhinoplasty, Primary and Revision, as well as Body Contouring after weight loss including post-bariatric reconstruction. His body contouring procedures are precise and transformative. His Rhinoplasties are elegant and refined. Practicing for over 30 years, Dr. Tom has become widely known for performing Closed Rhinoplasty, also referred to as Endonasal Rhinoplasty, nasal surgery performed by making all main incisions hidden inside. Based in Orlando, Florida, Dr. Tom is one of the most experienced and trusted cosmetic surgeons in the country. He has been featured in a wide range of top tier media outlets including The Doctors and won “Best Bets” by Orlando Sentinel for five consecutive years. He was named “Top Physician” by Orlando Family Magazine, “Top 100 Doctors” by Real Self from 2012 to 2019.

S16: - Earth’s natural balance to oily, acne- prone skin

Sulfur is one of nature’s most wonderful gifts to the skin. Created in the earth’s crust and found in abundance near volcanoes and hot springs, sulfur is a natural element and mineral that has been used for centuries to treat skin conditions, including acne vulgaris, dermatitis, and dandruff. Although it is recorded that Cleopatra bathed in sulfur, sulfur is still one of the most prominent ingredients when it comes to treating acne effectively. Alongside benzoyl peroxide and salicylic acid, sulfur makes up the third FDA-approved, over-the-counter acne-treating ingredient on the market. Knowing that sulfur is created by nature, found in the body, and FDA-approved, skin care professionals can feel confident recommending sulfur products and treatments to clients.

 

DECIPHERING THE SKIN

Sulfur is not for everyone or every skin type. The sulfur client is one who’s concern is excess oil; they may have mild to moderate acne and a thicker stratum corneum. Sulfur addresses all these concerns as it is antibacterial and inhibits the spread of P.acnes and keratolytic. This means it works to dry the epidermis, which then encourages desmosome detachment, and often the skin will lightly peel or flake. By removing this dead layer, it allows the antibacterial benefits to work more efficaciously as it treats the P.acnes at the site. With regular use the dryness should subside, leaving the client with a luminous, smooth, and clearer complexion.

 

REASSURING THE CLIENT

This powerfully effective ingredient may be too strong for clients who tend to be on the drier side and for those that have sensitive skin. Another caveat to note is the infamous smell. Often likened to rotten eggs, the sensorial experience can be less than pleasant for clients. The good news is that many products on the market have found ways to lessen the natural mineral odor, allowing for application to be more tolerable. If carrying sulfur-based products in the spa, consider applying to the back of the hands and timing how quickly the smell dissipates, it helps to share with on-the-fence clients.

 

PREVALENCE

When it comes to skin care products, sulfur is prevalent. Often found in over-the-counter products as an active ingredient, it ranges from 3% to 10%. More specifically, sulfur can be found in facial cleansers, creams, and masks and are often complemented by salicylic acid and benzoyl peroxide. Sulfur has proved over time to be a good addition to an oily, acne-prone skin care routine when used in conjunction with complimenting products and procedures. Clients will be in for a real treat as their skin will look healthier and clearer in little time.

High Expectations for Higher Results

In sports, you hear about the average team who won after they completed the unthinkable and won a championship against all the odds or an ordinary person who successfully starts and sells a billion-dollar company from nothing. But, what truly sets the team of destiny and determined entrepreneurs apart from others? How can skin care professionals learn from the success of others to enhance ourselves, both personally and professionally? The answer is found in the individual’s ability to set expectations for themselves and their teams that determine their success.

 When is the last time you have set or reset personal and professional expectations? If the answer is not recently, then it is time to raise the bar and elevate those expectations. In general, high expectations improve performance, whereas low expectations result in underachievement.

Every aspect of life is filled with expectations that set that are personal and those that are expected from others. Professionals must be prepared to provide excellent results if they plan to succeed in all aspects of life. There are a few proven methods to help us achieve success by setting higher expectations for themselves and those in the community. 

 

SET HIGH EXPECTATIONS FROM THE START 

In 1963 Robert Rosenthal and Lenore Jacobsen conducted a study in a classroom. The students took a test to identify those who were most likely to achieve academic success. Teachers were informed of the small group of students known as “growth spurters” who were expected to have the most promise. At the end of the school year, these students indeed soared high above their classmates academically. 

The catch? The overachievers had been chosen at random at the beginning of the study. The only difference between these students and their peers was that their teachers held them to a higher standard because they were under the impression these particular students were gifted and the teachers wanted to see them succeed.

The same idea may be used in the workplace. When employees and co-workers know that excellence is expected from the start, they are eager to go above and beyond what is asked to achieve success and stand out from the crowd. Setting the bar high for everyone sends a message that each person is expected to show above average results, and motivating their co-workers to keep up so that they do not fall behind. Managers should also have high-performance expectations of themselves, as this can lead to better results and more significant achievements for both themselves and their team. 

 

CELEBRATE THE SMALL VICTORIES

When an individual or team achieves success, whether big or small, positive reinforcement is the greatest resource available to continue to produce results. When an individual has dramatically improved performance over a short period, they should be recognized in order to celebrate this improvement and encourage continued growth that will then enhance continued success. A simple “great job” or “thank you for your hard work” will go a long way in keeping up morale in the workplace and give employees an extra boost of confidence that will push them towards continued excellence. 

 

ADDRESS FAILURES IMMEDIATELY 

When a task or project is not completed on time or is done incorrectly, it must not be ignored. Instead, the problem should be addressed head-on, making it known that failure is unacceptable. If it is a group effort, each participant should have the opportunity to discuss their individual contribution, one-on-one with their manager. This should be a time during which they and their manager walk through the steps of what went wrong and assess together what could have been done to convert the failure into a success. It is not a game of blame, but instead, encourages each person to improve on an individual level. Every individual has strengths and weaknesses and through these discussions, one can identify an area of strength while providing guidance on how to improve upon their weaknesses. Then evaluate what the team and manager can do to make it easier to come together for the next project to create a high level of success. 

As humans, we all make mistakes. It is essential to recognize that no one is perfect. By addressing failures head-on, it is easier to manage expectations moving forward and encourage individuals to press on and crave excellence, both in the workplace and in their personal lives.

 

PROVIDE ONGOING SUPPORT

When an employee, co-worker, or family member knows they have someone to back them up, they are much more likely to achieve a higher success rate. When faced with an overwhelming task that requires additional help, it is critical that they know what resources can be utilized to make each project into their most significant achievement to date.

Higher expectations really can lead to exceptional results, but only if the expectations are clear from the start and each person knows they have the necessary support that will help them achieve success.

Complete Results from Second Monotherapy Study of Abrocitinib Published

-Abrocitinib met all key endpoints, demonstrating statistically superior improvements in skin clearance, disease extent and severity, and itch compared to placebo-

-Safety profile consistent with other pivotal studies of abrocitinib reported to date-

Pfizer Inc. (NYSE: PFE) announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2) of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). Consistent with the first Phase 3 monotherapy study (JADE MONO-1), both doses of abrocitinib met all co-primary and key secondary endpoints and were generally well tolerated.

“Results from the second pivotal trial for abrocitinib reinforce the potential symptom relief it can offer those living with moderate to severe atopic dermatitis, including for itch — one of the most bothersome symptoms of AD,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We are hopeful that these findings, should abrocitinib be approved, will translate into meaningful improvements for patients who face daily challenges with this disease.”

JADE MONO-2 Trial Design

JADE MONO-2 was a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over 12 weeks. A total of 391 subjects with moderate to severe atopic dermatitis were randomized to abrocitinib 200mg, abrocitinib 100mg, and placebo in the trial.

Efficacy endpoints evaluated measures of improvements in skin clearance, disease extent and severity, and itch. The co-primary study endpoints in JADE MONO-2 were the proportion of patients who achieved:

an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin and two-point or greater improvement relative to baseline at Week 12.
at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) score at Week 12.
The key secondary endpoint was the proportion of patients achieving a four-point or larger reduction in itch severity measured with the Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 2, 4, and 12. The proportion of patients who achieved a 90% or greater change from baseline in EASI score at Week 12 was included as a secondary endpoint.

JADE MONO-2 Study Efficacy Results1

By Week 12, a greater proportion of patients on either dose of abrocitinib achieved the IGA, EASI-75, PP-NRS, and EASI-90 responses compared to those on placebo. The following co-primary efficacy and secondary endpoint results were seen at Week 12:



Abrocitinib 200mg (N=155)

Abrocitinib 100mg (N=158)

Placebo (N=78)

IGA Response Rate

38.1%

28.4%

9.1%

EASI-75 Response Rate

61.0%

44.5%

10.4%

PP-NRS ≥4-Point Improvement Response Rate

55.3%

45.2%

11.5%

EASI-90 Response Rate

37.7%

23.9%

3.9%


The proportion of patients achieving the IGA, EASI-75, PP-NRS, and EASI-90 responses were higher for abrocitinib treatment at each time point compared with placebo from Week 2 to Week 12, with responses seen as early as Week 2. Similar to JADE MONO 1, significant IGA, EASI-75, and PP-NRS responses were observed from Week 2 through Week 12.

JADE MONO-2 Study Safety Results 1

The most frequently reported treatment-emergent adverse events were nausea, nasopharyngitis, and atopic dermatitis in the abrocitinib 200mg, abrocitinib 100mg, and placebo groups, respectively.

Observed serious adverse events that were considered related to treatment were reported for two patients in the abrocitinib 100mg group (herpangina and pneumonia) and one patient with two events in the placebo group (eczema herpeticum and staphylococcal infection). There were no serious treatment-related adverse events in the 200mg group.

One patient with co-existing cardiovascular risk factors died from unknown etiology three weeks after receiving the last dose of abrocitinib 100mg once daily, which was deemed unrelated to the study drug by the investigator.

Other safety findings included:



Abrocitinib 200mg (N=155)

Abrocitinib 100mg (N=158)

Placebo (N=78)

Rate of Adverse Events

65.8%

62.7%

53.8%

Rate of Serious Adverse Events

1.3%

3.2%

1.3%

Rate of Discontinuation due to an Adverse Event

3.2%

3.8%

12.8%


The most frequently reported AEs leading to treatment discontinuation were headache in the abrocitinib 200mg group and atopic dermatitis in the abrocitinib 100mg and the placebo groups.

Additional Details About the JADE MONO-2 Study

Randomization was stratified by baseline disease severity (moderate [IGA=3] and severe [IGA=4] AD) and age (age 18 and ≥18 years). Concomitant use of topical or systemic therapies for AD or rescue medication was not permitted. Patients were permitted to use oral antihistamines and topical non-medicated emollients during the study. Eligible subjects completing the 12-week treatment period of the study had the option to enter a long-term extension (LTE) study, B7451015. Subjects discontinuing early from treatment, or who were otherwise ineligible for the LTE study, entered a 4-week follow up period in this study.

JADE MONO-2 is the second trial in the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program. Pfizer recently announced positive top-line results from the third trial in the program, JADE COMPARE. Additional data from other studies in the JADE program will be available later this year.

For additional information about JADE MONO-2, please visit https://www.clinicaltrials.gov.

About Abrocitinib

Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of atopic dermatitis, including interleukin (IL)-4, IL-13, IL-31, IL-22 and thymic stromal lymphopoietin (TSLP).

Abrocitinib received Breakthrough Therapy designation from the FDA for the treatment of patients with moderate to severe AD in February 2018. Breakthrough Therapy designation was initiated as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) signed in 2012. As defined by the FDA, a breakthrough therapy is a drug intended to be used alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as a Breakthrough Therapy, the FDA will expedite the development and review of such drug.2

About Atopic Dermatitis

AD is a chronic skin disease characterized by inflammation of the skin and skin barrier defects.3,4 Lesions of AD are characterized by erythema (redness), itching, induration (hardening)/papulation (formulation of papules), and oozing/crusting.3,4

AD is one of the most common, chronic, relapsing childhood dermatoses, affecting up to 10% of adults and up to 20% of children worldwide.5,6

About Pfizer’s Immunokinase Inhibitor Leadership

The JAK pathways are believed to play an important role in inflammatory processes as they are involved in signaling for over 50 cytokines and growth factors, many of which drive immune-mediated conditions.7 JAK inhibition may offer patients with these conditions a potential new advanced treatment option.8

Pfizer’s leading JAK biology and chemistry expertise combined with our research experience, has uniquely enabled the company to take a different R&D approach to that of other companies involved in JAK research, resulting in one of the broadest immunokinase inhibitor pipelines. Instead of studying a single molecule for all its potential uses, where it may not be optimal for some, Pfizer’s candidates with unique selectivity profiles are purposefully matched to the conditions where we believe they have the greatest potential to, if approved, address unmet need. Pfizer has five unique immunokinase inhibitors in late-stage clinical trials for the potential treatment of ten immune-mediated diseases:

Abrocitinib: A JAK1 inhibitor in phase 3 clinical trials for the potential treatment of moderate-to-severe AD among adolescents and adults
PF-06651600: An oral, JAK3/TEC family kinase inhibitor in a phase 3 clinical trial for the potential treatment of alopecia areata (AA) and in phase 2 for vitiligo, Crohn’s disease (CD), and ulcerative colitis (UC)
PF-06700841: A tyrosine kinase 2(TYK2)/JAK1 inhibitor in phase 2 clinical trials for the potential treatment of psoriasis and AD in topical formulation, and, in oral formulation for psoriatic arthritis, CD, UC, vitiligo, systemic lupus erythematosus (SLE), AA and hidradenitis suppurativa (HS)
PF-06826647: A TYK2 inhibitor under investigation in phase 2 clinical trials for the potential treatment of psoriasis and HS
PF-06650833: An IL-1 receptor associated kinase 4 (IRAK4) inhibitor under investigation for the potential treatment of rheumatoid arthritis and HS in phase 2 clinical trials
Pfizer Inc.: Breakthroughs that Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of June 3, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a product candidate, abrocitinib, and Pfizer’s ongoing investigational programs in kinase inhibitor therapies, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any jurisdictions for any potential indication for abrocitinib or any other investigational kinase inhibitor therapies; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether abrocitinib or any such other investigational kinase inhibitor therapies will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of abrocitinib or any other investigational kinase inhibitor therapies; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

___________________________________
1 Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. Published online June 03, 2020. doi:10.1001/jamadermatol.2020.1406.
2 U.S. Food and Drug Administration. Fact Sheet: Breakthrough Therapies at https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantA... accessed on August 16, 2019.
3 Hanifin JM, Reed ML. A population-based survey of eczema in the United States. Dermatitis. 2007;18(2):82-91.
4 Bieber T. Atopic dermatitis. Dermatology. 2012;1(3):203-217.
5 Oszukowska M, Michalak I, Gutfreund K, et al. Role of primary and secondary prevention in atopic dermatitis. Postep Derm Alergol. 2015:32(6):409-420.
6 Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
7 Banerjee, S., Biehl, A., Gadina, M. et al. JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017;77: 521. https://doi.org/10.1007/s40265-017-0701-9.
8 Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):3442–51. doi:10.1021/acschembio.6b00677.
  Pfizer.com

Read more...

Christine Valmy Delivers Largest Hand Sanitizer Donation Yet to Mount Sinai Hospital

Christine Valmy, creator of all-natural skin care products for consumers and professionals and operator of educational institutions in the field of beauty, today announced its largest donation of hand sanitizer yet, with a delivery to Mount Sinai Hospital – Visiting Doctors Program in New York City. This donation is the latest in its program to support healthcare workers and first responders during the Coronavirus pandemic.

The organization has committed to donating 10% of the total amount of hand sanitizer sold, in an initiative that began on April 23rd, 2020, and will continue until further notice. The donation program was kicked off with a delivery to The Mayor’s Fund to Advance New York City: COVID-19 Emergency Relief Fund. Other recipients include the Montville Township Police Department in New Jersey and the Milford Police Department in Massachusetts. Future recipients will be evaluated on an ongoing basis and reported on the donation program landing page on the company’s website.

Christine Valmy's two hand sanitizer products – Conditioning Hand Sanitizer and All-Natural Hand Sanitizing & Conditioning Gel – include nourishing ingredients like Aloe Vera and Vitamin E to moisturize the skin, leaving hands feeling soft rather than dried out. These gel sanitizers include 70% and 65% alcohol, respectively – above the CDC-recommended amount of alcohol to effectively disinfect the skin.

“While many of us are staying at home, our community’s heroes continue to put themselves at risk to help those who are sick, and to keep us all safe,” said Marina Valmy, President of Christine Valmy. “We are a small business, but we want to do what we can to help the people on the front lines of this pandemic. We have a unique hand sanitizer formula that does not dry the skin, which is important when you have to use it frequently. We’re hoping to bring some peace-of-mind and comfort to some of those who need it most during this difficult time.”

Christine Valmy’s consumer and professional products are available at https://shop.christinevalmy.com/



   

Read more...

Elelyft - New York Facial Plastic Surgeon Dr. Gary Linkov

Elelyft is a unique type of upper lip lift surgery that helps create extraordinary, yet natural-looking results by lifting the upper lip and creating facial symmetry. At City Facial Plastics, located in Manhattan, NYC, our goal is to help patients feel confident in their appearance. Dr. Gary Linkov is a top-rated plastic surgeon who uses cutting-edge techniques and technology for your lip augmentation to ensure every patient obtains natural-looking, stunning results.

What is Elelyft?

Elelyft is a unique type of upper lip lift surgery. Elelyft surgery is a variation of the bullhorn lip lift surgery that incorporates traditional upper lip lift surgery techniques with a modern and individualized approach in order to achieve the best results. Special surgical ink is used to mark the incision to ensure the exact, correct amount of skin will be removed and that the skin closure is precise.


Once the skin is removed, the modern surgical techniques of deep release and undermining of the remaining skin are performed. These additional steps reduce the tension of the skin, leading to more optimal wound closure and minimal scar formation.


How Did Elelyft Surgery Come to Be?

Dr. Linkov is always reading and researching surgical techniques that would help him provide the best results for his patients. Having had extensive training in facial anatomy and the science behind wound healing, Dr. Linkov knew that making the remaining upper lip skin as relaxed as possible before closing the incision during upper lip lift surgery would result in a less noticeable scar.


He also used the special surgical ink in facial reconstructive procedures in the past and decided to implement it for these cosmetic cases. Dr. Linkov has been using the Elelyft scarless upper lip lift surgery technique with excellent results.


A Cutting-Edge Approach to The Upper Lip Lift

The Elelyft procedure is a brand-new method that lifts the upper lip. The procedure draws on both older and newer concepts while adapting to each person’s unique features and desired outcome.


The upper lip lift has been around for some time and has often been requested by older patients looking for a lift after the inevitable effects of gravity and time. But now, the upper lip lift procedure is popular among all ages.



The Elelyft—Dr. Gary Linkov’s unique approach to the upper lip lift procedure—only requires a local anesthetic and leaves patients with more prominent and enhanced lips.


Are you interested in an upper lip lift? Contact the team at City Facial Plastics cosmetic surgery clinic in Midtown, Manhattan today. We’d love to tell you more about this procedure and answer any questions you might have.


What Does the Elelyft Procedure Involve?


The upper lip lift starts with a very meticulous marking and temporary skin staining to ensure the most accurate measurements and precision for closure. Dr. Gary Linkov may spend 20 to 30 minutes in this step to make sure the markings are as carefully done as possible since this is what will guide him through the process.


Once the marking is complete, Dr. Linkov will show the patient to make sure they are also happy with the markings and symmetry.

Once the patient approves the facial markings, Dr. Gary Linkov will move forward with local anesthesia to numb the upper lip so the rest of the procedure can be easily tolerated.


During the finishing touches of the surgery, there will be a sufficient release of tissues to provide a tension-free closure. The sutures used during the closure are strong enough to quickly heal the wound while also minimizing any scarring.


The Elelyft procedure respects the transition zone between the nose and the upper lip. Selecting the optimal amount of skin to remove is based on a unique set of parameters, taking into account the patient’s wishes and also establishing harmony for the oral complex and overall facial anatomy.


Read more: https://cityfacialplastics.com/elelyft-upper-lip-lift

City Facial Plastics
635 Madison Ave #1402E,
New York, NY 10022
(212) 439-5177
https://cityfacialplastics.com
City Facial Plastics 635 Madison Ave #1402E, New York, NY 10022
City Facial Plastics

Read more...

PUCA-Pure & Care Collagen Serum

This serum concentrate visibly reduces the appearance of wrinkles and fine lines. With the high content of soluble collagen, Pure & Care Collagen serum helps skin become more even, firmer, smoother and improves the skin’s elasticity. PUCA provides luxury wellness products at an affordable price point. Serums start at $10.

While this Nordic brand is paraben, silicon and cruelty-free, there’s more to its identity than the eco-friendly, scientifically-certified formulas it uses. PUCA – PURE & CARE values beauty, freedom, innovation and surprises creating anything but boring products within skin, hair and body care collections.

8582480082  https://pureandcare.dk/en/

Read more...

Webinar: The 5 Cs to Building and Sustaining a Skin Care Business In An Unprecedented Time

The 5 Cs to Building and Sustaining a Skin Care Business In An Unprecedented Time

In today’s unprecedented business and life climate everyone is beginning again. It has never been more important to have a plan and to be agile and able to adjust one’s business quickly. Skin care professionals must prepare to evolve.Whether a solo aesthetician or a spa business owner employing a staff, the 5 C’s to building and sustaining a business are most important. Clarity, creativity, courage, confidence, and compassion.

Join Megan Di Martino, a pioneer in the clinical medical spa industry, who has developed two result-oriented skin care product lines and owner of a luxury day and medical spa. Di Martino will delve into what skin care professionals can learn from the 5 C’s of business to build and sustain their business during an economic downturn and personal challenges.

MEET THE PRESENTER - MEGAN DIMARTINO!

Megan Di Martino is a lifelong creator of beauty, beginning her career in the fashion-beauty industries during the early 70’s in New York City. For over the last 25 years Di Martino has been one of the pioneers in result-oriented medical-grade skin care. She has built two skin care lines, Glycolique and Novita Spa Clinical products. In 2005, she opened her award winning “Hybrid Concept,” the Novita Spa and Medical Rejuvenation Clinic. It combines luxury spa services, clinical medical spa and regenerative stem cell wellness and aesthetic treatments. Recently she published her first book, “Hope and Possibilities Just Over the Horizon. It’s Never Too Early or Too Late to Create the Life of Your Dreams.” Today her passion and purpose is to help others to identify their passion and then actualize their dreams and goals through her consulting, training, and coaching programs.

 

 

 

 

 

The Best in the Biz

Anna Babinksa

Emily Davis

Elina Fedotova

Hailey Miller